US advisers back Pfizer’s inhaled insulin
‘Pfizer Inc.’s inhaled insulin powder neared U.S. approval on Thursday after scientific advisers said it could substitute for some of the injections many diabetics need to control blood sugar.
Sales of the product, Exubera, could top $2 billion a year as many of the 18 million U.S. diabetics opt for a needle-free way to treat their disease, some industry analysts predict.
Drug giant Pfizer is developing Exubera with French drug maker Sanofi-Aventis (SASY.PA) (NYSE:SNY - news) and Nektar Therapeutics, a small company that invented the insulin formulation and the inhaler for delivering it to the lungs.’
Read more at US advisers back Pfizer’s inhaled insulin
Recent Entries
- Sigma Pharmaceuticals year profit rises 27 pct
- South African citizens cheap drug guinea pigs
- Two drugs test victims face a year in coma
- Can drug companies improve their reputation?
- Pfizer Sees 40 Percent Rise in 2006 Net on Cost Cuts
- Pfizer’s Forecast Disappoints
- Pharmaceutical RFID Adoption Stalls
- Inhalable Drug Might Bring Sigh Of Relief To Diabetes Patients
- GlaxoSmithKline unveils best results since merger
- Pfizer Sues Teva, Sandoz Over Zithromax